{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:09Z","timestamp":1793176749167,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA069533"],"award-info":[{"award-number":["P30 CA069533"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018071","name":"Oregon Health & Science University Knight Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032128","name":"Taiho Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["CA250861"],"award-info":[{"award-number":["CA250861"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006370","name":"Small Business Innovation Research","doi-asserted-by":"publisher","award":["UL1TR002369"],"award-info":[{"award-number":["UL1TR002369"]}],"id":[{"id":"10.13039\/100006370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clcc.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:06:06Z","timestamp":1770192366000},"page":"249-257.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine\/Tipiracil With Concurrent Radiation in Resectable Stage II\/III Rectal Cancer: The FIERCE Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Emerson Y.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Nabavizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Kendsersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lessenich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Korngold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun M.","family":"Goodyear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen F.","family":"Kennecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Kardosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki Liana","family":"Tsikitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim C.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume Joe","family":"Pegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio G.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skye C.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Brinkerhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Taber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindha","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung S.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Charles R.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clcc.2026.02.001_bib0001","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.02.001_bib0003","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S1470-2045(15)00004-2","article-title":"Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial","volume":"16","author":"Garcia-Aguilar","year":"2015","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clcc.2026.02.001_bib0004","doi-asserted-by":"crossref","unstructured":"Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol. 2015;26(8):1722-8. doi:10.1093\/annonc\/mdv223","DOI":"10.1093\/annonc\/mdv223"},{"issue":"8","key":"10.1016\/j.clcc.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/annonc\/mdw215","article-title":"PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer","volume":"27","author":"Sclafani","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.001_bib0006","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.clcc.2026.02.001_bib0007","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.001_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2023.4845","article-title":"Practice patterns for organ preservation in US patients with rectal cancer, 2006-2020","volume":"10","author":"Loria","year":"2024","journal-title":"JAMA Oncol"},{"issue":"8","key":"10.1016\/j.clcc.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2026.02.001_bib0010","doi-asserted-by":"crossref","unstructured":"Leichman CG, McDonough SL, Smalley SR, et al. Cetuximab combined with induction oxaliplatin and capecitabine, followed by neoadjuvant chemoradiation for locally advanced rectal cancer: SWOG 0713. Clin Colorectal Cancer. 2018;17(1):e121-e125. doi:10.1016\/j.clcc.2017.10.008","DOI":"10.1016\/j.clcc.2017.10.008"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/annonc\/mdt516","article-title":"Phase I\/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer","volume":"25","author":"Blaszkowsky","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.001_bib0012","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1634\/theoncologist.2015-0106","volume":"20","author":"Landry","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2026.02.001_bib0013","doi-asserted-by":"crossref","unstructured":"Merx K, Martens UM, Kripp M, et al. Panitumumab in combination with preoperative radiation therapy in patients with locally advanced RAS wild-type rectal cancer: results of the Multicenter explorative single-arm phase 2 study NEORIT. Int J Radiat Oncol Biol Phys. 2017; 99 (4):867-875. doi:10.1016\/j.ijrobp.2017.06.2460","DOI":"10.1016\/j.ijrobp.2017.06.2460"},{"key":"10.1016\/j.clcc.2026.02.001_bib0014","doi-asserted-by":"crossref","unstructured":"Emura T, Nakagawa F, Fujioka A, et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med. 2004; 13 (2):249-55.","DOI":"10.3892\/ijmm.13.2.249"},{"key":"10.1016\/j.clcc.2026.02.001_bib0015","doi-asserted-by":"crossref","unstructured":"Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000;17(2):277-83. doi:10.3892\/ijo.17.2.277","DOI":"10.3892\/ijo.17.2.277"},{"key":"10.1016\/j.clcc.2026.02.001_bib0016","doi-asserted-by":"crossref","unstructured":"Tanaka N, Sakamoto K, Okabe H, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014; 32 (6):2319-26. doi:10.3892\/or.2014.3487","DOI":"10.3892\/or.2014.3487"},{"issue":"20","key":"10.1016\/j.clcc.2026.02.001_bib0017","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clcc.2026.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clcc.2026.02.001_bib0019","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12094-023-03268-5","article-title":"Efficacy and safety of trifluridine\/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis","volume":"26","author":"Huang","year":"2024","journal-title":"Clin Transl Oncol"},{"issue":"1-2","key":"10.1016\/j.clcc.2026.02.001_bib0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2017.10.044","article-title":"Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro","volume":"494","author":"Matsuoka","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clcc.2026.02.001_bib0021","doi-asserted-by":"crossref","unstructured":"Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res. 2016; 22 (17):4291-301. doi:10.1158\/1078-0432.CCR-16-0592","DOI":"10.1158\/1078-0432.CCR-16-0592"},{"issue":"2","key":"10.1016\/j.clcc.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"11","key":"10.1016\/j.clcc.2026.02.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv248","article-title":"Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial","volume":"107","author":"Allegra","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"36","key":"10.1016\/j.clcc.2026.02.001_bib0024","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","article-title":"Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer","volume":"30","author":"Gerard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clcc.2026.02.001_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clcc.2026.02.001_bib0026","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in THE case of THE binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1016\/j.clcc.2026.02.001_bib0027","doi-asserted-by":"crossref","unstructured":"Thiele B, Stein A, Schultheiss C, et al. Trifluridine\/tipiracil based chemoradiation in locally advanced rectal cancer: the phase I\/II TARC trial. Clin Colorectal Cancer. 2025;24(1):11-17. doi:10.1016\/j.clcc.2024.06.003","DOI":"10.1016\/j.clcc.2024.06.003"},{"key":"10.1016\/j.clcc.2026.02.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103312","article-title":"Total neoadjuvant therapy integrating long-course radiotherapy with trifluridine\/tipiracil for locally advanced rectal cancer: a single-arm, multicenter phase 2 trial","volume":"85","author":"Dou","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"10","key":"10.1016\/j.clcc.2026.02.001_bib0029","article-title":"Combination chemotherapy versus single-agent chemotherapy during preoperative chemoradiation for resectable rectal cancer","volume":"10","author":"Resende","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.clcc.2026.02.001_bib0030","article-title":"Controversies and perspectives in the current management of patients with locally advanced rectal cancer-a systematic review","volume":"15","author":"Stefan","year":"2025","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.clcc.2026.02.001_bib0031","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-024-12529-7","volume":"24","author":"Alvarez","year":"2024","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.clcc.2026.02.001_bib0032","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2026.02.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002826000083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:25:19Z","timestamp":1793175919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002826000083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1533002826000083"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2026.02.001","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine\/Tipiracil With Concurrent Radiation in Resectable Stage II\/III Rectal Cancer: The FIERCE Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}